Herpes zoster vaccine live: A 10 year review of post-marketing safety experience

Vaccine

Volumn 35, Issue 52, 2017, Pages 7231-7239

  Willis, English D ^a   Woodward, Meredith ^a   Brown, Elizabeth ^a   Popmihajlov, Zoran ^a   Saddier, Patricia ^a   Annunziato, Paula W ^a   Halsey, Neal A ^b   Gershon, Anne A ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Herpes zoster; Post marketing; Safety; Shingles vaccine live; Zoster vaccine live

Indexed keywords

VARICELLA ZOSTER VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EYE INFECTION; FEMALE; HERPES ZOSTER; HERPES ZOSTER OTICUS; HUMAN; INJECTION SITE REACTION; MALE; MIDDLE AGED; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RASH; VACCINATION; VERY ELDERLY; ADVERSE DRUG REACTION; EYE; FACTUAL DATABASE; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA; VARICELLA ZOSTER VIRUS; VIROLOGY;

AGED; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EYE; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION; VACCINES, ATTENUATED;

EID: 85034771901     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.11.013     Document Type: Article

References (46)

1. U.S. Food and Drug Administration. Approved Products: Zostavax. < http://wwwfdagov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm132831pdf> 2016. [Accessed 23 March 2017].
2. European Medicines Agency. Summary of Product Characterstics: Zostavax. < http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462pdf> 2016. [Accessed 23 March 2017].
3. Oxman, M.N., Levin, M.J., Johnson, G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005), 2271–2284.
4. Schmader, K.E., Levin, M.J., Gnann, J.W. Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 54 (2012), 922–928.
5. Schmader, K.E., Oxman, M.N., Levin, M.J., et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55 (2012), 1320–1328.
6. Morrison, V.A., Johnson, G.R., Schmader, K.E., et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60 (2015), 900–909.
7. Tseng, H.F., Smith, N., Harpaz, R., Bialek, S.R., Sy, L.S., Jacobsen, S.J., Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305 (2011), 160–166.
8. Langan, S.M., Smeeth, L., Margolis, D.J., Thomas, S.L., Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med, 10, 2013, e1001420.
9. Marin, M., Yawn, B.P., Hales, C.M., et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother 11 (2015), 1157–1164.
10. Tseng, H.F., Luo, Y., Shi, J., et al. Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis 62 (2016), 462–467.
11. Simberkoff, M.S., Arbeit, R.D., Johnson, G.R., et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Int Med 152 (2010), 545–554.
12. Murray, A.V., Reisinger, K.S., Kerzner, B., et al. Safety and tolerability of zoster vaccine in adults >/=60 years old. Hum Vaccin 7 (2011), 1130–1136.
13. Russell, A.F., Parrino, J., Fisher, C.L. Jr, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine 33 (2015), 3129–3134.
14. Mills, R., Tyring, S.K., Levin, M.J., et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 28 (2010), 4204–4209.
15. Macaladad, N., Marcano, T., Guzman, M., et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 25 (2007), 2139–2144.
16. Benson CHL, Andersen J, Jiang J, Bozzolo D, Annunziato P, Read S, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial CROI; 2012. Abstract #96.
17. Kerzner, B., Murray, A.V., Cheng, E., et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 55 (2007), 1499–1507.
18. MacIntyre, C.R., Egerton, T., McCaughey, M., et al. Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. Hum Vaccin 6 (2010), 894–902.
19. Gilderman, L.I., Lawless, J.F., Nolen, T.M., et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 15 (2008), 314–319.
20. Tyring, S.K., Diaz-Mitoma, F., Padget, L.G., et al. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. Vaccine 25 (2007), 1877–1883.
21. Baxter, R., Tran, T.N., Hansen, J., et al. Safety of Zostavax–a cohort study in a managed care organization. Vaccine 30 (2012), 6636–6641.
22. Chen, R.T., Glasser, J.W., Rhodes, P.H., et al. The Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 99 (1997), 765–773.
23. Tseng, H.F., Liu, A., Sy, L., et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Int Med 271 (2012), 510–520.
24. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E2D post-approval safety data management: definitions and standards for expedited reporting. < http://wwwichorg/products/guidelines/efficacy/efficacy-single/article/post-approval-safety-data-management-definitions-and-standards-for-expedited-reportinghtml> 2016. [Accessed 2 November 2016].
25. U.S. Food and Drug Administration. The FDA safety information and adverse event reporting program. < http://wwwfdagov/Safety/MedWatch/HowToReport/ucm053087htm> 2016. [Accessed 2 November 2016].
26. U.S. Food and Drug Administration. Draft guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines. < http://wwwfdagov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074850htm> 2016. [Accessed 2 November 2016].
27. LaRussa, P., Lungu, O., Hardy, I., Gershon, A., Steinberg, S.P., Silverstein, S., Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 66 (1992), 1016–1020.
28. Gershon ATM, Sewar J. Live attenuated varicella vaccine Vaccines. In: Plotkin S, Orenstein W, Offit P, editors. 6th ed. W.B. Saunders, Philadelphia; 2013.
29. Vaccine Adverse Event Reporting System. < https://vaershhsgov/index> 2017. [Accessed 10 March 2017].
30. Costa, E., Buxton, J., Brown, J., Templeton, K.E., Breuer, J., Johannessen, I., Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep, 2016, 2016.
31. Tseng, H.F., Schmid, D.S., Harpaz, R., et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis 58 (2014), 1125–1128.
32. Issa, N.P., Hentati, A., VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 84 (2015), 99–100.
33. Taylor, E., Exacerbation of herpes zoster ophthalmicus (HZO) following zoster vaccine, live, attenuated Oka/Merck: a case series. Pharmacoepidemiol Drug Saf, 10–01, 2013, 441.
34. Kennedy DGS, Lillie R. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. Chicester, United Kingdom: Wiley; 2000. p. 151–74.
35. Halsey, N.E.K., Dekker, C., Klein, N., Baxter, R., LaRussa, P., Marchant, C., et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine 30 (2012), 5791–5798.
36. Morrison, V.A., Oxman, M.N., Levin, M.J., et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 208 (2013), 559–563.
37. Galea, S.A., Sweet, A., Beninger, P., et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197:Suppl 2 (2008), S165–S169.
38. Institute of Medicine of the National Academies. Adverse effects of vaccines: evidence and causality. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. National Academies Press; Washington, DC; 2012.
39. Stratman, E., Visceral zoster as the presenting feature of disseminated herpes zoster. J Am Acad Dermatol 46 (2002), 771–774.
40. Rubin, L.G., Levin, M.J., Ljungman, P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (2014), e44–e100.
41. van Assen, S., Agmon-Levin, N., Elkayam, O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70 (2011), 414–422.
42. Singh, J.A., Saag, K.G., Bridges, S.L. Jr., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68 (2016), 1–25.
43. National Comprehensive Cancer Network, Inc., NCCN Guidelines for supportive care: survivorship. < https://wwwnccnorg/professionals/physician_gls/f_guidelinesasp#supportive> 2013. [Accessed 17 October 2016].
44. Government of Canada Advisory Committee Statement/National Advisory Committee on Immunization. Update on the use of herpes zoster vaccine. < http://publicationsgcca/site/eng/9698776/publicationhtml> 2014. [Accessed: 15 December 2015].
45. Public Health England. Shingles (herpes zoster). Green Book 2015; Chapter 28a. < https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448815/2904130_Green_Book_Chapter_28a_v1_0_0W_July2015.PDF> [Accessed: 28 July 2015].
46. Australian Government Department of Health. Zoster (herpes zoster). Australian Immunisation Handbook 2015; 10th Edition; Part 4.24. < http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbookpart4~handbook-4-24#4–1> [Accessed: 1 October 2015].